E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic malignant melanoma |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of 2 different dosing schedules of MS-275 in patients with metastatic melanoma |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety of MS-275 in patients with metastatic melanoma
To assess the pharmacokinetic profile of MS-275 in patients with metastatic melanoma
Optional substudies:
To assess the pharmacogenomic effects of MS-275 (participating sites and consenting patients only)
To assess the pharmacogenetic basis for response to MS-275 (participating sites and consenting patients only)
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1) Histologically confirmed nonresectable metastatic melanoma Stage III or IV (per American Joint Committee on Cancer/2002 criteria), 2) At least one and no more than two previous systemic therapies for metastatic melanoma (excluding prior systemic therapy given for lymph node metastasis as preoperative neoadjuvant and/or postoperative adjuvant therapy), 3) Presence of at least one lesion fulfilling the minimum RECIST size requirements for a target lesion (>=20 mm with conventional techniques or >=10 mm with spiral CT scan),
4) Able to undergo either contrast-enhanced CT scan or contrast-enhanced MRI scan for tumor assessment. 5) Lack of response to or progression after most recent systemic therapy for metastatic melanoma, 6) Life expectancy greater than 3 months, 7) Age >= 18 years, 8) Adequate organ and bone marrow functions as defined below: -- Absolute neutrophil count (ANC) >=1500/µl, -- Platelets >=100,000/µl, -- Creatinine <=1.5 x ULN or measured creatinine clearance of >=60 ml/min x 1.73 m2 BSA, -- Total bilirubin <=1.5 times upper limit of normal, -- AST (SGOT) 2/2ALT (SGPT) <=2.5 times upper limit of normal, 9) All AEs from prior anticancer therapy have resolved to 2Grade 1, 10) Able to swallow and retain intact investigational drug tablets, 11) Willingness and ability to return to the treatment center for follow-up as outlined in the protocol, 12) Have a negative serum pregnancy test within 2 weeks prior to receiving the first dose of study drug in female patients of childbearing potential. Agreement to use adequate method of contraception throughout the study period for sexually active males and females of childbearing potential, 13) Able to provide informed consent, 14) Able to complete all protocol requirements,
|
|
E.4 | Principal exclusion criteria |
1) Pregnancy, breast feeding, 2) Diagnosis of uveal melanoma, 3) Known history of HIV infection, 4) ECOG performance status >= 2, 5) Active malignancy in the 5 years prior to enrollment other than non-uveal melanoma, basal cell carcinoma, or cervical carcinoma in situ, 6) Ongoing effects from previous investigational drug studies or concomitant participation in other investigational drug studies 7) Prior use of MS-275 or any other HDAC inhibitor, 8) History of allergic reactions attributed to compounds of similar chemical or biologic composition to MS-275, 9) Known or suspected brain metastases, 10) Anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy, and hormone therapy) delivered within 4 weeks prior to the 1st dose of study drug, and 2 weeks prior for palliative “spot” radiotherapy to bone metastases), 11) Active gastrointestinal conditions (e.g., gastric resection, colitis, or prior intestinal surgery) that might predispose for poor drug absorption, 12) Major surgery (including but not limited to thoracic, abdominal, pelvic, or ophthalmologic surgery, neurosurgery, and large joint surgery such as knee or hip procedures) within 4 weeks prior to enrollment, 13) Concomitant use of corticosteroids (except when administered for refractory nausea/vomiting) or valproic acid, 14) Uncontrolled intercurrent illness—including but not limited to—ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, seizure disorder, or psychiatric illness/social situations that would limit compliance with study requirements, 15) Hypophosphatemia < 2.5 mg/dl (0.8 mmol/l) at screening, if not corrected in the screening period 16) Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study 17) Prior enrollment into this study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall tumor response rate defined as the proportion of patients with a best tumor response of PR or CR within the first 6 cycles of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Pharmacogenetic, pharmacogenomics |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |